UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
英国迷幻药：第三阶段抑郁症和酒精成瘾试验，新伦敦中心
The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ:CMPS) for Treatment-Resistant Depression and Awakn Life Sciences (OTC:AWKNF) for Severe Alcohol Use Disorder (SAUD).
英国药品和医疗保健监管局（MHRA）已批准了康帕思路径（纳斯达克股票代码：CMPS）针对耐药性抑郁症和Awakn Life Sciences（场外交易代码：AWKNF）针对严重酒精使用障碍（SAUD）进行的两项单独的3期试验。
Details On Trials
试用详情
Compass Pathways plc (NASDAQ:CMPS) will initiate the UK arm of its Phase 3 program on psilocybin therapy COMP360 for Treatment-Resistant Depression (TRD).
Compass Pathways plc（纳斯达克股票代码：CMPS）将在英国启动其针对耐药性抑郁症（TRD）的迷幻药疗法 COMP360 的第三阶段计划。
The ongoing program is reportedly the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. It consists of two pivotal trials, COMP 005 and COMP 006, each with an integrated long-term outcomes component.
据报道，正在进行的项目是有史以来最大的随机、对照、双盲迷幻药治疗临床项目。它由两项关键试验组成，即COMP 005和COMP 006，每项试验都包含综合的长期结果组成部分。
Following the MHRA...
该研究...
登录免费看全文
登录/注册